Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancerZongbi Yi, Fei Ma, Ling Yang et al.|npj Breast Cancer|2020Cited by 74
Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional DosageXiuwen Guan, Binghe Xu, Fei Ma et al.|Frontiers in Oncology|2020Cited by 52
Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancerXiuwen Guan, Fei Ma, Binliang Liu et al.|The Breast|2019Cited by 39
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective studyZongbi Yi, Binghe Xu, Fei Ma et al.|BMC Cancer|2019Cited by 33
Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysisZongbi Yi, Binghe Xu, Fei Ma et al.|Scientific Reports|2017Cited by 30